Signaling Pathways - ErbB - Insulin and Insulin-like Receptors
清除全部
- B1543 Mubritinib (TAK 165)中文名: 木利替尼Target: ErbBSummary: HER2/ErbB2有效抑制剂
- A8440 GSK1838705ATarget: Insulin and Insulin-like Receptors|ALKSummary: ATP竞争性IGF-IR/IR/ALK抑制剂
- A8375 AZD8931 (Sapitinib)中文名: 沙普替尼Target: EGFR|ErbBSummary: ErbB抑制剂
- A8319 Dacomitinib (PF299804, PF299)中文名: 达克替尼Target: ErbBSummary: HER抑制剂
- A1302 GSK1904529ATarget: Insulin and Insulin-like ReceptorsSummary: IGF-1R/IR 选择性抑制剂
- A1185 BMS-754807Target: Insulin and Insulin-like ReceptorsSummary: 有效的、选择性的IGF-1R和InsR抑制剂
- A8218 Lapatinib2 Citation中文名: 拉帕替尼Target: ErbBSummary: EGFR/HER2抑制剂
- A3608 MK 0893Target: Insulin and Insulin-like Receptors|Glucagon ReceptorsSummary: 胰高血糖素受体/ IGF-1R拮抗剂
- A4302 Rosiglitazone maleate中文名: 马来酸罗格列酮Target: Insulin and Insulin-like ReceptorsSummary: PPARγ激动剂,有效的胰岛素敏化剂
- A4092 CUDC-1011 CitationTarget: Histone Deacetylases (HDACs)|EGFR|ErbBSummary: 多靶点HDAC抑制剂